Jeeva Subbiah, Kim Ki-Hye, Shin Chong Hyun, Wang Bao-Zhong, Kang Sang-Moo
Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Vaccines (Basel). 2021 Aug 29;9(9):965. doi: 10.3390/vaccines9090965.
With the success of COVID-19 vaccines, newly created mRNA vaccines against other infectious diseases are beginning to emerge. Here, we review the structural elements required for designing mRNA vaccine constructs for effective in vitro synthetic transcription reactions. The unprecedently speedy development of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was enabled with previous innovations in nucleoside modifications during in vitro transcription and lipid nanoparticle delivery materials of mRNA. Recent updates are briefly described in the status of mRNA vaccines against SARS-CoV-2, influenza virus, and other viral pathogens. Unique features of mRNA vaccine platforms and future perspectives are discussed.
随着新冠病毒疫苗的成功，针对其他传染病的新型信使核糖核酸（mRNA）疫苗开始出现。在此，我们综述了设计用于有效的体外合成转录反应的mRNA疫苗构建体所需的结构元件。针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的mRNA疫苗此前在体外转录过程中的核苷修饰以及mRNA的脂质纳米颗粒递送材料方面的创新，使得其得以以前所未有的速度发展。本文简要介绍了针对SARS-CoV-2、流感病毒和其他病毒病原体的mRNA疫苗的最新情况。还讨论了mRNA疫苗平台的独特特征和未来展望。
